Nektar Therapeutics
(NASDAQ : NKTR)

( )
NKTR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading NKTR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.64%68.221.0%$511.57m
AMGNAmgen Inc.
-0.06%164.611.2%$473.08m
BIIBBiogen Inc.
-2.41%279.981.2%$433.18m
CELGCelgene Corporation
-0.26%125.201.1%$368.74m
REGNRegeneron Pharmaceuticals, Inc.
-0.25%371.392.7%$306.45m
VRTXVertex Pharmaceuticals Incorporated
-0.79%116.341.8%$289.18m
INCYIncyte Corporation
-1.05%123.082.1%$252.04m
ALXNAlexion Pharmaceuticals, Inc.
0.15%120.731.6%$213.99m
ILMNIllumina, Inc.
1.70%184.583.3%$188.12m
TSROTESARO, Inc.
2.58%142.0115.3%$145.06m
NBIXNeurocrine Biosciences, Inc.
-0.63%53.284.5%$109.21m
BMRNBioMarin Pharmaceutical Inc.
2.00%96.074.3%$103.70m
KITEKite Pharma, Inc.
2.77%82.8015.6%$98.74m
CLVSClovis Oncology, Inc.
1.35%58.6418.2%$88.77m
AAgilent Technologies, Inc.
0.06%54.841.6%$88.10m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.